Martin Nicklasson, Phd
Dr Nicklasson was appointed Chair of the Kymab Board in June 2017. He has held a number of senior positions at AstraZeneca plc including Executive Vice President of Global Marketing and Business Development and EVP of Global Drug Development. He was CEO of Biovitrum AB and Swedish Orphan Biovitrum AB and is currently Chair of the boards of Orexo AB and Zealand Pharma A/S.
Dr Nicklasson also serves as a board member of Basilea Pharmaceutica Ltd and Biocrine AB. He previously served as a board member of Scandinavian Life science invest AB, Denator AB, Pozen Inc., Oasmia AB, Farma Investment AS, PledPharma AB, BioInvent International AB, Premier Research Group Ltd and EffRx Pharmaceuticals SA. He is a certified pharmacist and holds a PhD in Pharmaceutical Technology from the Uppsala University, where he is Associate Professor at the Department of Pharmaceutics.
David Chiswell, PhD
Chief Executive Officer
Dr Chiswell has over 30 years' experience in the biotechnology industry having co-founded Cambridge Antibody Technology (CAT) in 1990, serving as CEO from 1996 to 2002. CAT listed on the London Stock exchange in April 1997 and Nasdaq in June 2001, and was subsequently sold to AstraZenca where it forms an important part of their biopharmaceutical franchise.
Since leaving CAT in 2002, he has focused on the development of early-stage biotechnology companies, having previously served as a director of Arakis, non-executive chairman of Sosei, Arrow Therapeutics and Daniolabs, and as CEO of Nabriva Therapeutics (2009 to 2012). Dr Chiswell currently serves as chairman of Albireo Pharma and is a director of Nabriva Therapeutics. He is a past chairman of the UK BioIndustry association (BIA) and in 2006 he was awarded the Most Excellent Order of the British Empire (OBE) by Her Majesty the Queen for services to the biotechnology industry.
Allan Bradley, PhD FRS
Chief Technical Officer
Professor Bradley completed his PhD studies in genetics at the University of Cambridge in 1984. Working with Liz Robertson in the laboratory of Martin Evans, who shared the Nobel Prize for Physiology or Medicine in 2007, they showed that embryonic stem cells could be used to stably modify mouse genes.
In 1987 Professor Bradley moved to Baylor College of Medicine, Houston, Texas, where his laboratory developed novel methods to engineer the genomes of mice. He was appointed Investigator with the Howard Hughes Medical Institute in 1993 and full Professor in 1994. In 2000, Dr Bradley returned to the UK as Director of the Welcome Trust Sanger Institute.
Professor Bradley is the author of almost 300 scientific articles and book chapters. He has been active in commercialising technology from his laboratory by founding several companies including a publicly traded genomics company, Lexicon Genetics Inc.
In July 2002 he was elected Fellow of the Royal Society. In 2010 he was appointed Emeritus Director of the Sanger Institute, to support the development of Kymab, the first spin-out company launched by the Sanger institute.
Adrian Howd, PhD
Dr Howd is a Director of Malin Corporation plc ("Malin"). Malin is an Irish incorporated public limited company which applies its long term capital and proven operational and strategic expertise to a select number of private life science companies.
Previously, Dr Howd has held both sell-side and buy-side roles, being a highly ranked sell-side analyst at Berenberg, Nomura and ABN Amro where he was Global Head of Healthcare Research. He also gained buy-side experience running a healthcare portfolio as part of the Principal Strategies Group at ABN Amro. Dr. Howd also served as Executive Vice President, Head of Neuroscience and Corporate Development at Evotec AG. Dr. Howd has a PhD in molecular neuroscience from the University of London.
Christian Itin, PhD
Dr Itin currently serves as the Chief Executive Officer of Autolus Ltd, a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours. Dr Itin is a leader in the immuno-oncology field.
Previously he served as President and CEO at Micromet Inc., a former NASDAQ-listed biopharmaceutical company, which was acquired in 2012 by Amgen. At Micromet, Dr Itin and his team pioneered the field of T-cell engaging antibodies, or BiTEs. The lead programme, blinatumomab, obtained approval by the FDA as breakthrough therapy for the treatment of patients with acute lymphoblastic leukemia. Dr Itin spent 13 years with Micromet in a number of senior management roles, becoming CEO in 2004.
He continues to serve as Chairman of Autolus and Kuros Biosciences AG. From November 2012 to January 2016 he served as Chief Executive Officer and Chairman of Cytos Biotechnology Ltd.
Ms Patel is Head of Direct Private Investments at the Wellcome Trust and looks after its Direct Private portfolio valued at over $1B. Direct Private Investments back a range of companies from technology, ecommerce and healthcare businesses to energy and financial services firms. Ms Patel joined The Wellcome Trust in 2006 and has worked across multiple asset classes.
Prior to joining The Wellcome Trust she worked at Lazard, an advisory investment bank, in their London corporate finance practice. She currently serves on the Investment Committees of Pembroke College, Oxford and the Honourable Society of the Middle Temple. Ms Patel is a CFA Charterholder and read Economics & Management at the University of Oxford.
Timothy J Rink, MD, ScD
Dr Rink is former Chairman and Chief Executive Officer of Aurora Biosciences Corporation, a drug discovery technology company in San Diego, California. He is currently a board member of Cambridge Epigenetix Ltd and Genome Research Ltd.
Over the past 20 years, Dr Rink has also served on the boards of Adnexus Therapeutics, Alanex, Ciphergen, CoCensys, Gryphon Sciences, Nova, NPS and Sepracor in the USA, and AkuBio, Astex Therapeutics, BioVex, Lorantis, and Santhera in Europe; he served as chair of the technology transfer strategy panel of the Wellcome Trust from 2002 to 2008. Dr Rink was President and Chief Technical Officer of Amylin Pharmaceuticals Inc. from 1990 to 1995, and was Vice-President for Research at SmithKline from 1984 to 1989.
Prior to this he was a lecturer in physiology at the University of Cambridge. He received his MA, MD and ScD degrees from the University of Cambridge.
Edward Walker-Arnott, LLM
Mr Walker-Arnott gained extensive experience as a commercial lawyer at the international law firm Herbert Smith, where he was Senior Partner and is currently a consultant. He has served as a non-executive director of two listed companies in the manufacturing and insurance industries. He was a member of the departmental committee (the Cork Committee) that reviewed insolvency law and whose recommendations are enshrined in the current law.
He was one of the first three outsiders (nominated by the Bank of England) to sit on the governing body of the Lloyds insurance market. From 2003 to 2004 he sat on the small advisory group assisting Sir David Clementi in his review of the regulatory framework for legal services, implemented as the Legal Services Act 2007. He has served as on the Board of Governors of The Wellcome Trust since 2000 and is a Visiting Professor at University College London, where he teaches company law.
Timothy Wells, PhD
Dr Wells is Chief Scientific Officer of Medicines for Malaria Venture (MMV), Geneva. Prior to joining MMV, Tim was Senior Executive Vice President Research at Serono and brought several innovative molecules into clinical studies. From 1997 to 2007, he worked at the Glaxo Institute for Molecular Biology in Geneva, where he ran Protein Biochemistry, and led the research on chemotactic cytokines. An enzymologist by training, his research interests include protein structure function relationships, and the role of cytokines in controlling host responses.
Tim has over 180 scientific publications and several patent applications. He has a PhD in Chemistry from Imperial College, London for Protein Engineering studies on enzyme catalysis, with Sir Alan Fersht. He was awarded a ScD in Biology from the University of Cambridge for his later work on Cytokine Biology, and is a Fellow of the Royal Society of Chemistry, and the UK Academy of Medical Sciences.
Ms Yip is a Senior Program Investment Officer on the Program Related Investments (PRI) team at the Bill & Melinda Gates Foundation (BMGF). The PRI team manages the foundation's $1.5B PRI pool which focuses on strategic investments in global health, global development and US education. Within BMGF, Ms Yip oversees investments across multiple Foundation priorities ranging from biotech to education technology companies. She also represents the foundation on numerous boards.
Prior to joining BMGF, Ms Yip was a Vice President in the Investment Banking Division at Goldman Sachs and worked in New York, Hong Kong and San Francisco from 2002 to 2012 and as the Business Unit Manager for the West Coast Offices. Ms Yip read History and Science at Harvard University from where she graduated magna cum laude.